Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

HSP27 Expression as a Novel Predictive Biomarker for Bevacizumab: is it Cost Effective?

Seo MK, Straume O, Akslen LA, Cairns J.

Pharmacoecon Open. 2020 Jan 27. doi: 10.1007/s41669-019-00193-8. [Epub ahead of print]

2.

ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab.

Forthun RB, Hovland R, Schuster C, Puntervoll H, Brodal HP, Namløs HM, Aasheim LB, Meza-Zepeda LA, Gjertsen BT, Knappskog S, Straume O.

Sci Rep. 2019 Nov 25;9(1):17471. doi: 10.1038/s41598-019-53917-5.

3.

Are 90% of deaths from cancer caused by metastases?

Dillekås H, Rogers MS, Straume O.

Cancer Med. 2019 Sep;8(12):5574-5576. doi: 10.1002/cam4.2474. Epub 2019 Aug 8.

4.

Dynamic hospital competition under rationing by waiting times.

Sá L, Siciliani L, Straume OR.

J Health Econ. 2019 Jul;66:260-282. doi: 10.1016/j.jhealeco.2019.06.005. Epub 2019 Jun 19.

PMID:
31306867
5.

Competition and physician behaviour: Does the competitive environment affect the propensity to issue sickness certificates?

Brekke KR, Holmås TH, Monstad K, Straume OR.

J Health Econ. 2019 Jul;66:117-135. doi: 10.1016/j.jhealeco.2019.05.007. Epub 2019 May 21.

PMID:
31181454
6.

Distant metastasis dynamics following subsequent surgeries after primary breast cancer removal.

Demicheli R, Dillekås H, Straume O, Biganzoli E.

Breast Cancer Res. 2019 May 2;21(1):57. doi: 10.1186/s13058-019-1139-7.

7.

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.

Jansen YJL, Rozeman EA, Mason R, Goldinger SM, Geukes Foppen MH, Hoejberg L, Schmidt H, van Thienen JV, Haanen JBAG, Tiainen L, Svane IM, Mäkelä S, Seremet T, Arance A, Dummer R, Bastholt L, Nyakas M, Straume O, Menzies AM, Long GV, Atkinson V, Blank CU, Neyns B.

Ann Oncol. 2019 Jul 1;30(7):1154-1161. doi: 10.1093/annonc/mdz110.

PMID:
30923820
8.

Elevated plasma interleukin 6 predicts poor response in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.

Pilskog M, Nilsen GH, Beisland C, Straume O.

Cancer Treat Res Commun. 2019;19:100127. doi: 10.1016/j.ctarc.2019.100127. Epub 2019 Mar 14.

9.

The link between wound healing and escape from tumor dormancy.

Dillekås H, Straume O.

Surg Oncol. 2019 Mar;28:50-56. doi: 10.1016/j.suronc.2018.11.009. Epub 2018 Nov 9. Review.

PMID:
30851911
10.

Competition and equity in health care markets.

Siciliani L, Straume OR.

J Health Econ. 2019 Mar;64:1-14. doi: 10.1016/j.jhealeco.2018.12.002. Epub 2018 Dec 21.

PMID:
30654150
11.

Predictive value of angiogenic proteins in patients with metastatic melanoma treated with bevacizumab monotherapy.

Schuster C, Akslen LA, Stokowy T, Straume O.

J Pathol Clin Res. 2019 Jan;5(1):53-62. doi: 10.1002/cjp2.116. Epub 2018 Nov 9.

12.

Tumour cell expression of interleukin 6 receptor α is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.

Pilskog M, Bostad L, Edelmann RJ, Akslen LA, Beisland C, Straume O.

J Pathol Clin Res. 2018 Apr;4(2):114-123. doi: 10.1002/cjp2.96. Epub 2018 Mar 5.

13.

Socio-economic status and physicians' treatment decisions.

Brekke KR, Holmås TH, Monstad K, Straume OR.

Health Econ. 2018 Mar;27(3):e77-e89. doi: 10.1002/hec.3621. Epub 2017 Dec 6.

PMID:
29210134
14.

Association of Warfarin Use With Lower Overall Cancer Incidence Among Patients Older Than 50 Years.

Haaland GS, Falk RS, Straume O, Lorens JB.

JAMA Intern Med. 2017 Dec 1;177(12):1774-1780. doi: 10.1001/jamainternmed.2017.5512.

15.

Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.

Pilskog M, Beisland C, Akslen LA, Bostad L, Haug Å, Heinrich D, Hjelle KM, Straume O.

BMC Urol. 2017 Aug 31;17(1):74. doi: 10.1186/s12894-017-0267-6.

16.

Competition policy for health care provision in Norway.

Brekke KR, Straume OR.

Health Policy. 2017 Feb;121(2):134-140. doi: 10.1016/j.healthpol.2016.11.013. Epub 2016 Nov 23.

PMID:
27916434
17.

Reference pricing with endogenous generic entry.

Brekke KR, Canta C, Straume OR.

J Health Econ. 2016 Dec;50:312-329. doi: 10.1016/j.jhealeco.2016.04.003. Epub 2016 Jun 8.

PMID:
27350294
18.

Patient mobility and health care quality when regions and patients differ in income.

Brekke KR, Levaggi R, Siciliani L, Straume OR.

J Health Econ. 2016 Dec;50:372-387. doi: 10.1016/j.jhealeco.2016.05.003. Epub 2016 May 30.

PMID:
27344297
19.

The recurrence pattern following delayed breast reconstruction after mastectomy for breast cancer suggests a systemic effect of surgery on occult dormant micrometastases.

Dillekås H, Demicheli R, Ardoino I, Jensen SAH, Biganzoli E, Straume O.

Breast Cancer Res Treat. 2016 Jul;158(1):169-178. doi: 10.1007/s10549-016-3857-1. Epub 2016 Jun 15.

20.
21.

Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report.

Tzoulis C, Schwarzlmüller T, Gjerde IO, Søfteland E, Neckelmann G, Biermann M, Haroche J, Straume O, Vintermyr OK.

BMC Res Notes. 2015 Apr 30;8:171. doi: 10.1186/s13104-015-1135-7.

22.

Differences in metastatic patterns in relation to time between primary surgery and first relapse from breast cancer suggest synchronized growth of dormant micrometastases.

Dillekås H, Transeth M, Pilskog M, Assmus J, Straume O.

Breast Cancer Res Treat. 2014 Aug;146(3):627-36. doi: 10.1007/s10549-014-3057-9. Epub 2014 Jul 20.

23.

Patient choice, mobility and competition among health care providers.

Brekke KR, Gravelle H, Siciliani L, Straume OR.

Dev Health Econ Public Policy. 2014;12:1-26. Review.

PMID:
24864380
24.

Spontaneous reversion of the angiogenic phenotype to a nonangiogenic and dormant state in human tumors.

Rogers MS, Novak K, Zurakowski D, Cryan LM, Blois A, Lifshits E, Bø TH, Oyan AM, Bender ER, Lampa M, Kang SY, Naxerova K, Kalland KH, Straume O, Akslen LA, Watnick RS, Folkman J, Naumov GN.

Mol Cancer Res. 2014 May;12(5):754-64. doi: 10.1158/1541-7786.MCR-13-0532-T. Epub 2014 Feb 26.

25.

Malignant melanoma--diagnosis, treatment and follow-up in Norway.

Geisler J, Bachmann IM, Nyakas M, Helsing P, Fjøsne HE, Mæhle LO, Aamdal S, Eide NA, Svendsen HL, Straume O, Robsahm TE, Jacobsen KD, Akslen LA.

Tidsskr Nor Laegeforen. 2013 Oct 29;133(20):2154-9. doi: 10.4045/tidsskr.12.1416. Review. English, Norwegian.

26.

Nestin expression is associated with aggressive cutaneous melanoma of the nodular type.

Ladstein RG, Bachmann IM, Straume O, Akslen LA.

Mod Pathol. 2014 Mar;27(3):396-401. doi: 10.1038/modpathol.2013.151. Epub 2013 Sep 13.

27.

Vascular proliferation is associated with survival in pancreatic ductal adenocarcinoma.

Hoem D, Straume O, Immervoll H, Akslen LA, Molven A.

APMIS. 2013 Nov;121(11):1037-46. doi: 10.1111/apm.12057. Epub 2013 Mar 13.

PMID:
23489215
28.

Tumor vasculature: the Achilles' heel of cancer?

Johannessen TC, Wagner M, Straume O, Bjerkvig R, Eikesdal HP.

Expert Opin Ther Targets. 2013 Jan;17(1):7-20. doi: 10.1517/14728222.2013.730522. Epub 2012 Nov 2. Review.

PMID:
23121690
29.

Tumor necrosis is a prognostic factor in thick cutaneous melanoma.

Ladstein RG, Bachmann IM, Straume O, Akslen LA.

Am J Surg Pathol. 2012 Oct;36(10):1477-82. doi: 10.1097/PAS.0b013e31825a5b45.

PMID:
22982891
30.

Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension.

Schuster C, Eikesdal HP, Puntervoll H, Geisler J, Geisler S, Heinrich D, Molven A, Lønning PE, Akslen LA, Straume O.

PLoS One. 2012;7(6):e38364. doi: 10.1371/journal.pone.0038364. Epub 2012 Jun 15.

31.

Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer.

Straume O, Shimamura T, Lampa MJ, Carretero J, Øyan AM, Jia D, Borgman CL, Soucheray M, Downing SR, Short SM, Kang SY, Wang S, Chen L, Collett K, Bachmann I, Wong KK, Shapiro GI, Kalland KH, Folkman J, Watnick RS, Akslen LA, Naumov GN.

Proc Natl Acad Sci U S A. 2012 May 29;109(22):8699-704. doi: 10.1073/pnas.1017909109. Epub 2012 May 15.

32.

Prognostic importance of the mitotic marker phosphohistone H3 in cutaneous nodular melanoma.

Ladstein RG, Bachmann IM, Straume O, Akslen LA.

J Invest Dermatol. 2012 Apr;132(4):1247-52. doi: 10.1038/jid.2011.464. Epub 2012 Feb 2.

33.

Vascular proliferation is a prognostic factor in breast cancer.

Arnes JB, Stefansson IM, Straume O, Baak JP, Lønning PE, Foulkes WD, Akslen LA.

Breast Cancer Res Treat. 2012 Jun;133(2):501-10. doi: 10.1007/s10549-011-1785-7. Epub 2011 Sep 27.

PMID:
21947750
34.

Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancer.

Akslen LA, Straume O, Geisler S, Sørlie T, Chi JT, Aas T, Børresen-Dale AL, Lønning PE.

Br J Cancer. 2011 Jun 28;105(1):9-12. doi: 10.1038/bjc.2011.203. Epub 2011 Jun 14.

35.

Competition and quality in health care markets: a differential-game approach.

Brekke KR, Cellini R, Siciliani L, Straume OR.

J Health Econ. 2010 Jul;29(4):508-23. doi: 10.1016/j.jhealeco.2010.05.004. Epub 2010 Jun 12.

PMID:
20542342
36.

Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.

Ladstein RG, Bachmann IM, Straume O, Akslen LA.

BMC Cancer. 2010 Apr 14;10:140. doi: 10.1186/1471-2407-10-140.

37.

Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.

Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK, Jänne P, Kobayashi S, Halmos B, Tenen D, Tang XM, Engelman J, Yeap B, Folkman J, Johnson BE, Heymach JV.

Clin Cancer Res. 2009 May 15;15(10):3484-94. doi: 10.1158/1078-0432.CCR-08-2904. Epub 2009 May 15.

38.

Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas.

Bachmann IM, Ladstein RG, Straume O, Naumov GN, Akslen LA.

BMC Cancer. 2008 Dec 5;8:362. doi: 10.1186/1471-2407-8-362.

39.

Tumor-vascular interactions and tumor dormancy.

Naumov GN, Folkman J, Straume O, Akslen LA.

APMIS. 2008 Jul-Aug;116(7-8):569-85. doi: 10.1111/j.1600-0463.2008.01213.x. Review.

PMID:
18834403
40.

Tumor dormancy due to failure of angiogenesis: role of the microenvironment.

Naumov GN, Folkman J, Straume O.

Clin Exp Metastasis. 2009;26(1):51-60. doi: 10.1007/s10585-008-9176-0. Epub 2008 Jun 18.

PMID:
18563595
41.

Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma.

Akslen LA, Puntervoll H, Bachmann IM, Straume O, Vuhahula E, Kumar R, Molven A.

Melanoma Res. 2008 Feb;18(1):29-35. doi: 10.1097/CMR.0b013e3282f32517.

PMID:
18227705
42.

Reference pricing of pharmaceuticals.

Brekke KR, Königbauer I, Straume OR.

J Health Econ. 2007 May 1;26(3):613-42. Epub 2006 Dec 22.

PMID:
17188769
43.

Gatekeeping in health care.

Brekke KR, Nuscheler R, Straume OR.

J Health Econ. 2007 Jan;26(1):149-70. Epub 2006 Aug 4.

PMID:
16890313
44.

Bevacizumab therapy for POEMS syndrome.

Straume O, Bergheim J, Ernst P.

Blood. 2006 Jun 15;107(12):4972-3; author reply 4973-4. No abstract available.

PMID:
16754779
45.

A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype.

Naumov GN, Bender E, Zurakowski D, Kang SY, Sampson D, Flynn E, Watnick RS, Straume O, Akslen LA, Folkman J, Almog N.

J Natl Cancer Inst. 2006 Mar 1;98(5):316-25.

PMID:
16507828
46.

Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma.

Bachmann IM, Straume O, Puntervoll HE, Kalvenes MB, Akslen LA.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8606-14.

47.

EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.

Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP, Akslen LA.

J Clin Oncol. 2006 Jan 10;24(2):268-73. Epub 2005 Dec 5.

PMID:
16330673
49.

BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival.

Akslen LA, Angelini S, Straume O, Bachmann IM, Molven A, Hemminki K, Kumar R.

J Invest Dermatol. 2005 Aug;125(2):312-7.

50.

Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas.

Bachmann IM, Straume O, Akslen LA.

Int J Oncol. 2004 Dec;25(6):1559-65.

PMID:
15547691

Supplemental Content

Loading ...
Support Center